Update and review of adult polycystic kidney disease

被引：39

作者：

Colbert, Gates B. ^{[1
]}

Elrggal, Mohamed E. ^{[2
]}

Gaur, Lovy ^{[3
]}

Lerma, Edgar, V ^{[4
]}

机构：

[1] Baylor Univ, Med Ctr Dallas, Waco, TX 76798 USA

[2] Kidney & Urol Ctr, Alexandria, Egypt

[3] Max Superspecial Hosp, Vaishali, India

[4] UIC Advocate Christ Med Ctr, Oak Lawn, IL USA

来源：

DM DISEASE-A-MONTH | 2020年 / 66卷 / 05期

关键词：

Autosomal dominant kidney disease; End stage kidney disease; Tolvaptan; Kidney cyst; Hypertension; ANGIOTENSIN-ALDOSTERONE SYSTEM; CARDIOVASCULAR-ABNORMALITIES; EXTRARENAL MANIFESTATIONS; RENAL-TRANSPLANTATION; VOLUME PROGRESSION; BLOOD-PRESSURE; CYST GROWTH; GENE; PREVALENCE; HYPERTENSION;

D O I：

10.1016/j.disamonth.2019.100887

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autosomal dominant polycystic kidney disease is a common cause of end stage kidney disease. It is a progressive and unfortunately incurable condition that can lead to significant morbidity and kidney failure. Many more patients are diagnosed with this disease without any symptoms as the population is increasingly undergoing imaging for other problems and diagnostic workup. Our understanding of the genetic variants has increased in recent years as research continues to improve. As well, therapeutic options have developed with the FDA approval of a new treatment medication, with many others underway. This review updates the clinician on the pathophysiology, clinical aspects, and therapeutic options for patients the is form of kidney disease. (C) 2019 Elsevier Inc. All rights reserved.

引用

页数：14

共 98 条

[1] Management of ESRD in Patients With Autosomal Dominant Polycystic Kidney Disease [J].